Table 2

Information of envelopes used for assays
Env ID Clade Location Mode of transmission Length of infection Mo/yr isolated Corecepter
Du172.17 C South Africa M-F 12 weeks Nov-98 R5
ZM214M.PL15 C Zambia F-M <13 weeks Jul-03 R5
CAP210.2.00.E8 C South Africa M-F 5 weeks May-05 R5
CHN19 C China R5
HIV16936-2 EF117270 C India F-M 1 week Nov-00 R5
Q168.ENV.B23 A Kenya M-F 1 week R5
Q461.ENV.C2 A Kenya M-F 4 weeks R5
HIV env 6235 clone 3 B USA M-M 6 weeks Mar-95 R5
PVO clone 4 B Italy M-M 4 weeks Jan-96 R5
pRHPA 4259 clone7 B USA M-F < weeks Dec-00 R5
pTHRO4156 clone 18 B USA M-M 1 week Aug-00 R5
SC 422661.8 B Trinidad F-M 4 weeks Jan-95 R5
SF162 B USA R5
93TH975-15 E Haiti F-M <18 weeks Jan-93 R5

Primary envelopes from various clade was chosen based to have a diversity of locations and mode of mocusal transmission. Envelopes were used to test the presence of binding and neutralizing antibodies elicited by vaccination of consensus vaccines in non-human primates. SF162 was included because it is the challenge virus envelope.

Eugene et al.

Eugene et al. Virology Journal 2013 10:102   doi:10.1186/1743-422X-10-102

Open Data